


What is claimed is:

1. A compound having a structure set forth in formula (I):



wherein:

- (a) R<sub>4</sub>-R<sub>6</sub>, and R<sub>8</sub>-R<sub>10</sub> are hydrogen;
- (b) R<sub>1</sub>, R<sub>2</sub>, and R<sub>3</sub> are each independently selected from the group consisting of hydrogen, halogen, carboxylic acid, optionally substituted ester, optionally substituted amide, optionally substituted alkyl, optionally substituted alkoxy, trihalomethyl, optionally substituted aryl, and optionally substituted heteroaryl; and
- (c) R<sub>7</sub> is selected from the group consisting of substituted alkyl and substituted alkoxy;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1, wherein:

- (a) R<sub>1</sub> is selected from the group consisting of hydrogen and optionally substituted alkyl;
- (b) R<sub>2</sub> and R<sub>3</sub> are each independently selected from the group consisting of hydrogen, halo, carboxylic acid, optionally substituted heteroaryl, and optionally substituted phenyl; and
- (c) R<sub>7</sub> is selected from the group consisting of lower alkyl substituted with a heteroaliphatic ring or dialkylamino and lower alkoxy substituted with a heteroaliphatic ring or dialkylamino.

3. The compound of Claim 2 wherein:

- (a) R<sub>1</sub> is selected from the group consisting of hydrogen;

- (b) R<sub>2</sub> is hydrogen, halo, phenyl, or carboxylic acid; and
- (c) R<sub>3</sub> is hydrogen, halo, carboxylic acid, optionally substituted pyridyl, and phenyl optionally substituted with lower alkoxy or halo; and
- (d) R<sub>7</sub> is lower alkyl substituted with a heteroaliphatic ring or dialkylamino.

4. The compound of Claim 3 wherein R<sub>7</sub> is selected from the group consisting of 3-diethylaminopropyl and 3-pyrrolidin-1-yl-propyl.

5. The compound of Claim 3 wherein:

- (a) R<sub>1</sub> is selected from the group consisting of hydrogen;
- (b) R<sub>2</sub> is hydrogen, halo, phenyl, or carboxylic acid;
- (c) R<sub>3</sub> is hydrogen, halo, carboxylic acid, optionally substituted pyridyl, and phenyl optionally substituted with lower alkoxy or halo; and
- (d) R<sub>7</sub> is lower alkoxy substituted with a heteroaliphatic ring or dialkylamino.

6. The compound of claim 5, wherein R<sub>7</sub> is selected from the group consisting of 2-dimethylaminoethoxy, 2-diethylaminoethoxy, 2-pyrrolidin-1-yl-ethoxy, and 2-morpholin-4-yl-ethoxy.

7. A compound selected from the group consisting of :

3-[5-(3-diethylamino-propyl)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,

5-bromo-3-[5-(3-diethylamino-propyl)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,

3-[5-(3-diethylamino-propyl)-1*H*-indol-2-ylmethylene]-6-phenyl-1,3-dihydro-indol-2-one,

3-[5-(3-diethylamino-propyl)-1*H*-indol-2-ylmethylene]-5-phenyl-1,3-dihydro-indol-2-one,

3-[5-(2-dimethylamino-ethoxy)-1*H*-indol-2-ylmethylene]-5-phenyl-1,3-dihydro-indol-2-one,

, 5-phenyl-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,

3-[5-(2-morpholin-4-yl-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one

5-bromo-3-[5-(2-morpholin-4-yl-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,

3-[5-(2-morpholin-4-yl-ethoxy)-1*H*-indol-2-ylmethylene]-6-phenyl-1,3-dihydro-indol-2-one,

3-[5-(2-dimethylamino-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,

5-bromo-3-[5-(2-dimethylamino-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,

3-[5-(2-dimethylamino-ethoxy)-1*H*-indol-2-ylmethylene]-6-phenyl-1,3-dihydro-indol-2-one,

3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,

5-bromo-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,

6-phenyl-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,

3-[5-(2-diethylamino-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,

5-bromo-3-[5-(2-diethylamino-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,

3-[5-(2-diethylamino-ethoxy)-1*H*-indol-2-ylmethylene]-6-phenyl-1,3-dihydro-indol-2-one,

3-[5-(2-diethylamino-ethoxy)-1*H*-indol-2-ylmethylene]-5-phenyl-1,3-dihydro-indol-2-one,

3-[5-(3-diethylamino-propyl)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,

5-bromo-3-[5-(3-diethylamino-propyl)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,

3-[5-(3-diethylamino-propyl)-1*H*-indol-2-ylmethylene]-6-phenyl-1,3-dihydro-indol-2-one,

3-[5-(3-diethylamino-propyl)-1*H*-indol-2-ylmethylene]-5-phenyl-1,3-dihydro-indol-2-one,

3-[5-(3-pyrrolidin-1-yl-propyl)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,

2-oxo-3-[5-(3-pyrrolidin-1-yl-propyl)-1*H*-indol-2-ylmethylene]-2,3-dihydro-1*H*-indol-5-carboxylic acid,

2-oxo-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-2,3-dihydro-1*H*-indole-5-carboxylic acid,

2-oxo-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-2,3-dihydro-1*H*-indole-6-carboxylic acid,

4-(2-hydroxy-ethyl)-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,

6-pyridin-3-yl-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,

6-(4-methoxy-phenyl)-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,

6-(3-methoxy-phenyl)-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,

6-(2-methoxy-phenyl)-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,

6-(4-fluoro-phenyl)-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,

3-[5-(2-morpholin-4-yl-ethoxy)-1*H*-indol-2-ylmethylene]-2-oxo-2,3-dihydro-1*H*-indole-5-carboxylic acid,

3-[5-(2-morpholin-4-yl-ethoxy)-1*H*-indol-2-ylmethylene]-2-oxo-2,3-dihydro-1*H*-indole-6-carboxylic acid,

3-[5-(2-morpholin-4-yl-ethoxy)-1*H*-indol-2-ylmethylene]-5-phenyl-1,3-dihydro-indol-2-one,

4-(2-hydroxy-ethyl)-3-[5-(2-morpholin-4-yl-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,

3-[5-(2-morpholin-4-yl-ethoxy)-1H-indol-2-ylmethylene]-6-pyridin-3-yl-1,3-dihydro-indol-2-one,

6-(4-methoxy-phenyl)-3-[5-(2-morpholin-4-yl-ethoxy)-1H-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,


6-(3-methoxy-phenyl)-3-[5-(2-morpholin-4-yl-ethoxy)-1H-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,

6-(2-methoxy-phenyl)-3-[5-(2-morpholin-4-yl-ethoxy)-1H-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,

and 6-(4-fluoro-phenyl)-3-[5-(2-morpholin-4-yl-ethoxy)-1H-indol-2-ylmethylene]-1,3-dihydro-indol-2-one;


or a pharmaceutically acceptable salt thereof.

8. An indolinone compound having a structure set forth in formula (II):



wherein:

- (a)  $R_{11}$ - $R_{14}$  are hydrogen;
- (b)  $R_{15}$  and  $R_{16}$  are each independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted aryl, and optionally substituted heteroaryl, or  $R_{15}$  and  $R_{16}$  taken together with the nitrogen atom to which they are attached form a ring structure selected from the group consisting of a five-membered or six-membered heteroaromatic ring, a five-membered or six-membered heteroaliphatic ring, a nine-membered fused bicyclic heteroaromatic ring, and a ten-membered fused bicyclic heteroaromatic ring; and
- (c) A is selected from the group consisting of formula (III), (IV), and (V):



wherein:

- (i) R<sub>19</sub>-R<sub>25</sub> and R<sub>27</sub>-R<sub>31</sub> are hydrogen;
- (ii) R<sub>17</sub> and R<sub>18</sub> are each independently selected from the group consisting of hydrogen, optionally substituted alkyl, and optionally substituted alkoxy provided that both R<sub>17</sub> and R<sub>18</sub> are not hydrogen; and
- (iii) R<sub>26</sub> is selected from the group consisting of optionally substituted alkyl; or a pharmaceutically acceptable salt thereof.

9. The compound of claim 8, wherein:

- (i) R<sub>15</sub> is hydrogen or alkyl;
- (ii) R<sub>16</sub> is hydrogen, alkyl, phenyl optionally substituted with one or two substituents selected from halo or unsubstituted lower alkyl or 5 or 6 membered heteroaryl; or R<sub>15</sub> and R<sub>16</sub> together with the nitrogen to which they are attached form 2,3-dihydroindol-1-yl, 2,3-dihydro-2H-quinolin-1-yl, or 2,3-dihydro-2H-isoquinolin-2-yl ring wherein said rings are optionally substituted with halo or alkyl;
- (iii) R<sub>17</sub> is hydrogen, methyl, or methoxy;
- (iv) R<sub>18</sub> is selected from the group consisting of lower alkoxy substituted with heteroalicyclic; and
- (v) A is group of formula III.

10. The compound of claim 8, wherein:

- (i) R<sub>15</sub> is hydrogen or methyl;

(ii)  $R_{16}$  is hydrogen, methyl, isopropyl, phenyl, pyridin-3-yl, 3-chlorophenyl, or 4-chloro-2-fluorophenyl, or  $R_{15}$  and  $R_{16}$  together with the nitrogen atom to which they are attached form 2,3-dihydroindol-1-yl, 2,3-dihydro-2H-quinolin-1-yl, 5-bromo-2,3-dihydro-2H-quinolin-1-yl, or 2,3-dihydro-2H-isoquinolin-2-yl;

(iii)  $R_{17}$  is selected from the group consisting of hydrogen, methyl, and methoxy; and

(iv)  $R_{18}$  is selected from the group consisting of hydrogen, 2-pyrrolidin-1-yl-ethoxy and 2-morpholin-4-yl-ethoxy;

11. The compound of claim 8, wherein:

(i)  $R_{15}$  is hydrogen or alkyl;

(ii)  $R_{16}$  is hydrogen, alkyl, phenyl optionally substituted with one or two substituents selected from halo or unsubstituted lower alkyl or 5 or 6 membered heteroaryl; or

(iii)  $R_{15}$  and  $R_{16}$  together with the nitrogen to which they are attached form 2,3-dihydroindol-1-yl, 2,3-dihydro-2H-quinolin-1-yl, or 2,3-dihydro-2H-isoisoquinolin-2-yl ring wherein said rings are optionally substituted with halo or alkyl;

(iv)  $R_{26}$  is selected from the group consisting of optionally substituted alkyl; and

(v) A is group of formula IV.

12. The compound of claim 8, wherein:

(i)  $R_{15}$  is hydrogen or methyl;

(ii)  $R_{16}$  is hydrogen, methyl, isopropyl, phenyl, pyridin-3-yl, 3-chlorophenyl, or 4-chloro-2-fluorophenyl, or  $R_{15}$  and  $R_{16}$  together with the nitrogen atom to which they are attached form 2,3-dihydroindol-1-yl, 2,3-dihydro-2H-quinolin-1-yl, 5-bromo-2,3-dihydro-2H-quinolin-1-yl, or 2,3-dihydro-2H-isoisoquinolin-2-yl; and

(iii)  $R_{26}$  is methyl.

13. The compound of claim 8, wherein:

(i) R<sub>15</sub> is hydrogen or alkyl;

(ii) R<sub>16</sub> is hydrogen, alkyl, phenyl optionally substituted with one or two substituents selected from halo or unsubstituted lower alkyl, 5 or 6 membered heteroaryl; or

R<sub>15</sub> and R<sub>16</sub> together with the nitrogen to which they are attached form 2,3-dihydroindol-1-yl, 2,3-dihydro-2H-quinolin-1-yl, or 2,3-dihydro-2H-isoisoquinolin-2-yl ring wherein said rings are optionally substituted with halo or alkyl; and

(iii) A is group of formula V.

14. The compound of claim 8, wherein:

(i) R<sub>15</sub> is hydrogen or methyl; and

(ii) R<sub>16</sub> is hydrogen, methyl, isopropyl, phenyl, pyridin-3-yl, 3-chlorophenyl, or 4-chloro-2-fluorophenyl, or R<sub>15</sub> and R<sub>16</sub> together with the nitrogen atom to which they are attached form 2,3-dihydroindol-1-yl, 2,3-dihydro-2H-quinolin-1-yl, 5-bromo-2,3-dihydro-2H-quinolin-1-yl, or 2,3-dihydro-2H-isoisoquinolin-2-yl; and

(iii) A is group of formula V.

15. A compound selected from the group consisting of:

2-oxo-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-2,3-dihydro-1*H*-indole-5-sulfonic acid amide,

3-[5-(2-morpholin-4-yl-ethoxy)-1*H*-indol-2-ylmethylene]-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid amide,

2-oxo-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-2,3-dihydro-1*H*-indole-5-sulfonic acid methylamide,

2-oxo-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-2,3-dihydro-1*H*-indole-5-sulfonic acid dimethylamide,

2-oxo-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-2,3-dihydro-1*H*-indole-5-sulfonic acid isopropylamide,

2-oxo-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-2,3-dihydro-1*H*-indole-5-sulfonic acid phenylamide,



2-oxo-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-2,3-dihydro-1*H*-indole-5-sulfonic acid pyridin-3-ylamide,

5-(2,3-dihydro-indole-1-sulfonyl)-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,

2-oxo-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-2,3-dihydro-1*H*-indole-5-sulfonic acid (3-chloro-phenyl)-amide,

2-oxo-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-2,3-dihydro-1*H*-indole-5-sulfonic acid (3-chloro-phenyl)-methyl-amide,

2-oxo-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-2,3-dihydro-1*H*-indole-5-sulfonic acid (4-chloro-2-fluoro-phenyl)-amide,

5-(3,4-dihydro-2*H*-quinoline-1-sulfonyl)-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,

5-(3,4-dihydro-1*H*-isoquinoline-2-sulfonyl)-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,

5-(5-bromo-2,3-dihydro-indole-1-sulfonyl)-3-[5-(2-pyrrolidin-1-yl-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,

3-[5-(2-morpholin-4-yl-ethoxy)-1*H*-indol-2-ylmethylene]-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid methylamide,

3-[5-(2-morpholin-4-yl-ethoxy)-1*H*-indol-2-ylmethylene]-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid dimethylamide,

3-[5-(2-morpholin-4-yl-ethoxy)-1*H*-indol-2-ylmethylene]-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid isopropylamide,

3-[5-(2-morpholin-4-yl-ethoxy)-1*H*-indol-2-ylmethylene]-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid phenylamide,

3-[5-(2-morpholin-4-yl-ethoxy)-1*H*-indol-2-ylmethylene]-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid pyridin-3-ylamide,

5-(2,3-dihydro-indole-1-sulfonyl)-3-[5-(2-morpholin-4-yl-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,

3-[5-(2-morpholin-4-yl-ethoxy)-1*H*-indol-2-ylmethylene]-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid (3-chloro-phenyl)-amide,

3-[5-(2-morpholin-4-yl-ethoxy)-1*H*-indol-2-ylmethylene]-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid (3-chloro-phenyl)-methyl-amide,

3-[5-(2-morpholin-4-yl-ethoxy)-1*H*-indol-2-ylmethylene]-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid (4-chloro-2-fluoro-phenyl)-amide,

5-(3,4-dihydro-2*H*-quinoline-1-sulfonyl)-3-[5-(2-morpholin-4-yl-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,

5-(3,4-dihydro-1*H*-isoquinoline-2-sulfonyl)-3-[5-(2-morpholin-4-yl-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,

5-(5-bromo-2,3-dihydro-indole-1-sulfonyl)-3-[5-(2-morpholin-4-yl-ethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,

3-(1*H*-indol-3-ylmethylene)-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid amide,

3-(2-methyl-1*H*-indol-3-ylmethylene)-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid amide,

3-(1*H*-indol-5-ylmethylene)-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid amide,

3-(1*H*-indol-3-ylmethylene)-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid methylamide,

3-(2-methyl-1*H*-indol-3-ylmethylene)-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid methylamide,

3-(1*H*-indol-5-ylmethylene)-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid methylamide,

3-(1*H*-indol-2-ylmethylene)-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid methylamide,

3-(1*H*-indol-3-ylmethylene)-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid dimethylamide,

3-(2-methyl-1*H*-indol-3-ylmethylene)-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid dimethylamide,



3-(1*H*-indol-5-ylmethylene)-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid dimethylamide,

3-(1*H*-indol-2-ylmethylene)-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid dimethylamide,

and 3-(4-methoxy-1*H*-indol-2-ylmethylene)-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid methylamide;

or a pharmaceutically acceptable salt thereof.


16. A combinatorial library of at least five indolinone compounds that can be formed by reacting an oxindole with an aldehyde wherein said oxindole has a structure set forth in formula VII or VIII, or a pharmaceutically acceptable salt thereof:



wherein

- (a) R<sub>51</sub>-R<sub>54</sub>, R<sub>64</sub>, and R<sub>65</sub> are hydrogen;
- (b) R<sub>55</sub> and R<sub>56</sub> are each independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted aryl, and optionally substituted heteroaryl, or when taken together R<sub>55</sub> and R<sub>56</sub> form an optionally substituted five-membered or six-membered heteroaliphatic ring;
- (c) R<sub>61</sub>-R<sub>63</sub> are each independently selected from the group consisting of hydrogen, halogen, carboxylic acid, optionally substituted aryl, optionally substituted heteroaryl, and amide; and


wherein said aldehyde has a structure set forth in formula (IX)



wherein

- (d) R<sub>71</sub> and R<sub>73</sub>-R<sub>75</sub> are hydrogen;
- (e) R<sub>72</sub> is selected from the group consisting of hydrogen, optionally substituted alkyl, and optionally substituted alkoxy.

17. The combinatorial library of claim 16, wherein:

- (a) R<sub>55</sub> and R<sub>56</sub> are each independently selected from the group consisting of hydrogen, methyl, isopropyl, 2-methoxyethyl, benzyl, 4-fluorobenzyl, 2-methoxyphenyl, 3-fluorophenyl, 4-fluorophenyl, 3-chlorophenyl, 3-pyridyl, or when taken together R<sub>55</sub> and R<sub>56</sub> form a ring selected from the group consisting of pyrrole, 4-methylpiperazine;
- (b) R<sub>61</sub>-R<sub>63</sub> are each independently selected from the group consisting of hydrogen, bromo, phenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 3-pyridyl, -COOH, -C(O)NHCH<sub>2</sub>CH<sub>3</sub>, -C(O)NHCH<sub>2</sub>C(O)OH, -C(O)NHCH(CH<sub>3</sub>)C(O)OH, -C(O)NHCH(CH(CH<sub>3</sub>)<sub>2</sub>)C(O)OH, and
- 
- (c) R<sub>72</sub> is selected from the group consisting of hydrogen 2-diethylamino-ethoxy, and 3-pyrrolidin-1-yl-propyl.

18. The combinatorial library of claim 16, wherein:

- (a) said aldehyde is selected from the group consisting of 2-formyl-1*H*-indole, 2-formyl-5-(3-diethylamino-propyl)-1*H*-indole, 2-formyl-5-(2-diethylaminoethoxy)-1*H*-indole, and 2-formyl-5-(3-pyrrolidin-1-yl-propyl)-1*H*-indol; and
- (b) said oxindole is selected from the group consisting of
- 2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid amide,
  - 2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid methylamide,
  - 2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid dimethylamide,
  - 2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid (4-chloro-2-fluoro-phenyl)-ethyl-amide,
  - 5-(2,3-dihydro-indole-1-sulfonyl)-1,3-dihydro-indol-2-one,
  - 2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid (4-chloro-2-fluoro-phenyl)-methyl-amide,
  - 2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid (4-chloro-2-fluoro-phenyl)-amide,
  - 5-phenyl-1,3-dihydro-indol-2-one,

2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid [2-(4-methoxy-phenyl)-2-oxo-ethyl]-amide,

2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid (3-methoxy-phenyl)-amide, N-(2-oxo-2,3-dihydro-1*H*-indol-5-yl)-benzamide,

cyclopentanecarboxylic acid (2-oxo-2,3-dihydro-1*H*-indol-5-yl)-amide,

(2-oxo-2,3-dihydro-1*H*-indol-5-yl)-carbamic acid benzyl ester,

2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid 4-fluoro-benzylamide,

2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid [3-(2-oxo-pyrrolidin-1-yl)-propyl]-amide,

2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid (1,2,3,4-tetrahydro-naphthalen-1-yl)-amide,

2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid (furan-2-ylmethyl)-amide,

3-(2-oxo-2,3-dihydro-1*H*-indole-5-sulfonylamino)-thiophene-2-carboxylic acid methyl ester,

2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid (3-chloro-phenyl)-amide,

2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid m-tolylamide,

2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid (2-hydroxy-ethyl)-amide,

4-(2-oxo-2,3-dihydro-1*H*-indole-5-sulfonyl)-piperazine-1-carboxylic acid ethyl ester,

4-(2-oxo-2,3-dihydro-1*H*-indole-5-sulfonyl)-piperazine-1-carbaldehyde,

2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid (2-methoxy-ethyl)-amide,

2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid propylamide, 5-(4-methyl-piperazine-1-sulfonyl)-1,3-dihydro-indol-2-one,

2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid benzylamide, 2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid (2-methoxy-phenyl)-amide,

2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid cyclopropylamide,

2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid pyridin-3-ylamide,

2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid phenylamide,

5-(pyrrolidine-1-sulfonyl)-1,3-dihydro-indol-2-one,

5-(4-acetyl-piperazine-1-sulfonyl)-1,3-dihydro-indol-2-one,

2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid cyclohexylamide,

2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid (2-morpholin-4-yl-ethyl)-amide,

2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid cyclobutylamide,

2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid (1-phenyl-ethyl)-amide,

2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid cyclopentylamide,

5-(2-pyrrolidin-1-yl-acetyl)-1,3-dihydro-indol-2-one,

N-(2-oxo-2,3-dihydro-1*H*-indole-5-yl)-acetamide,

(2-oxo-2,3-dihydro-1*H*-indole-5-yl)-carbamic acid tert-butyl ester,

2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid isopropylamide,

toluene-4-sulfonic acid 2-(2-oxo-2,3-dihydro-1*H*-indole-4-yl)-ethyl ester,

2-oxo-2,3-dihydro-1*H*-indole-4-carboxylic acid ethylamide,

4-phenyl-1,3-dihydro-indol-2-one,

2-oxo-2,3-dihydro-1*H*-indole-4-carboxylic acid (4-methoxy-phenyl)-amide,

4-(2-morpholin-4-yl-ethyl)-1,3-dihydro-indol-2-one,

4-(2-pyrrolidin-1-yl-ethyl)-1,3-dihydro-indol-2-one,

4-[2-(4-methyl-piperazin-1-yl)-ethyl]-1,3-dihydro indol-2-one,

4-[2-(3-bromo-phenoxy)-ethyl]-1,3-dihydro-indol-2-one,

4-(2-bromo-ethyl)-1,3-dihydro-indol-2-one,

4-(2-bromo-ethyl)-1,3-dihydro-indol-2-one,

2-oxo-2,3-dihydro-1*H*-indole-4-carboxylic acid (6-methoxy-4'-methylsulfanyl-biphenyl-3-yl)-amide,

2-oxo-2,3-dihydro-1*H*-indole-4-carboxylic acid (4-methoxy-3-thiophen-3-yl-phenyl)-amide,

2-oxo-2,3-dihydro-1*H*-indole-4-carboxylic acid biphenyl-3-ylamide,

2-oxo-2,3-dihydro-1*H*-indole-4-carboxylic acid (6-methoxy-3'-trifluoromethyl-biphenyl-3-yl)-amide,

2-oxo-2,3-dihydro-1*H*-indole-4-carboxylic acid (4'-fluoro-6-methoxy-biphenyl-3-yl)-amide,

2-oxo-2,3-dihydro-1*H*-indole-4-carboxylic acid (6-methoxy-[1,1',4',1'']terphenyl-3-yl)-amide,

2-oxo-2,3-dihydro-1*H*-indole-4-carboxylic acid (6,4'-dimethoxy-biphenyl-3-yl)-amide,

2-oxo-2,3-dihydro-1*H*-indole-4-carboxylic acid (3-chloro-4-methoxy-phenyl)-amide,  
 isopropyl-carbamic acid 2-(2-oxo-2,3-dihydro-1*H*-indol-4-yl)-ethyl ester,  
 4-[2-(3-trifluoromethyl-phenoxy)-ethyl]-1,3-dihydro-indol-2-one,  
 4-[2-(5-chloro-pyridin-3-yloxy)-ethyl]-1,3-dihydro-indol-2-one,  
 4-[2-(4-methoxy-phenoxy)-ethyl]-1,3-dihydro-indol-2-one,  
 4-(2-ethoxy-ethyl)-1,3-dihydro-indol-2-one,  
 4-(2-methoxy-ethyl)-1,3-dihydro-indol-2-one,  
 ethyl-carbamic acid 2-(2-oxo-2,3-dihydro-1*H*-indol-4-yl)-ethyl ester,  
 biphenyl-2-yl-carbamic acid 2-(2-oxo-2,3-dihydro-1*H*-indol-4-yl)-ethyl ester,  
 6-pyridin-3-yl-1,3-dihydro-indol-2-one,  
 6-phenyl-1,3-dihydro-indol-2-one,  
 6-(2-methoxy-phenyl)-1,3-dihydro-indol-2-one,  
 6-(3-methoxy-phenyl)-1,3-dihydro-indol-2-one, 6-(4-methoxy-phenyl)-1,3-dihydro-indol-2-one,  
 and cyclohexyl-carbamic acid 2-(2-oxo-2,3-dihydro-1*H*-indol-4-yl)-ethyl ester;  
 or a pharmaceutically acceptable salt thereof.

19. The combinatorial library of claim 16, wherein said reaction of an oxindole with an aldehyde forms a compound selected from the group consisting of  
 3-[5-(3-diethylamino-propyl)-1*H*-indol-2-ylmethylene]-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid dimethyl amide,  
 3-[5-(3-diethylamino-propyl)-1*H*-indol-2-ylmethylene]-5-(4-methyl-piperazine-1-sulfonyl)-1,3-dihydro-indol-2-one,  
 3-[5-(3-diethylamino-propyl)-1*H*-indol-2-ylmethylene]-5-(pyrrolidine-1-sulfonyl)-1,3-dihydro-indol-2-one,  
 3-[5-(3-diethylamino-propyl)-1*H*-indol-2-ylmethylene]-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid (2-methoxy-ethyl)-amide,  
 3-[5-(3-diethylamino-propyl)-1*H*-indol-2-ylmethylene]-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid pyridin-3-ylamide,

3-[5-(3-diethylamino-propyl)-1*H*-indol-2-ylmethylene]-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid (2-methoxy-phenyl)amide,

3-[5-(3-diethylamino-propyl)-1*H*-indol-2-ylmethylene]-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid (3-chlorophenyl)amide,

3-[5-(3-diethylamino-propyl)-1*H*-indol-2-ylmethylene]-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid (4-fluorobenzyl)amide,

3-[5-(3-diethylamino-propyl)-1*H*-indol-2-ylmethylene]-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid amide,

3-[5-(3-diethylamino-propyl)-1*H*-indol-2-ylmethylene]-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid isopropylamide,

3-(1*H*-indol-2-ylmethylene)-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid benzylamide,

3-(1*H*-indol-2-ylmethylene)-5-(pyrrolidine-1-sulfonyl)-1,3-dihydro-indol-2-one,

3-(1*H*-indol-2-ylmethylene)-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid (2-methoxyethyl)amide,

3-(1*H*-indol-2-ylmethylene)-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid (2-methoxyphenyl)amide,

3-(1*H*-indol-2-ylmethylene)-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid (3-chlorophenyl)amide,

3-(1*H*-indol-2-ylmethylene)-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid (4-fluorobenzyl)amide,

3-(1*H*-indol-2-ylmethylene)-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid amide,

3-(1*H*-indol-2-ylmethylene)-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid methylamide,

3-(1*H*-indol-2-ylmethylene)-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid dimethylamide,

3-(1*H*-indol-2-ylmethylene)-2-oxo-2,3-dihydro-1*H*-indole-5-sulfonic acid isopropylamide,

5-bromo-3-[5-(2-diethylaminoethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,



3-[5-(2-diethylaminoethoxy)-1*H*-indol-2-ylmethylene]-6-(3-methoxyphenyl)-1,3-dihydro-indol-2-one,

3-[5-(2-diethylaminoethoxy)-1*H*-indol-2-ylmethylene]-6-(4-methoxyphenyl)-1,3-dihydro-indol-2-one,

3-[5-(2-diethylaminoethoxy)-1*H*-indol-2-ylmethylene]-6-phenyl-1,3-dihydro-indol-2-one,

3-[5-(2-diethylaminoethoxy)-1*H*-indol-2-ylmethylene]-6-(2-methoxyphenyl)-1,3-dihydro-indol-2-one,

3-[5-(2-diethylaminoethoxy)-1*H*-indol-2-ylmethylene]-2-oxo-2,3-dihydro-1*H*-indole-4-carboxylic acid ethylamine,

6-bromo-3-[5-(2-diethylaminoethoxy)-1*H*-indol-2-ylmethylene]-1,3-dihydro-indol-2-one,

3-[5-(2-diethylaminoethoxy)-1*H*-indol-2-ylmethylene]-6-pyridin-1,3-dihydro-indol-2-one,

3-[5-(2-diethylaminoethoxy)-1*H*-indol-2-ylmethylene]-5-phenyl-1,3-dihydro-indol-2-one,

3-[5-(2-diethylaminoethoxy)-1*H*-indol-2-ylmethylene]-2-oxo-2,3-dihydro-1*H*-indole-4-carboxylic acid (3-chloro-4-methoxyphenyl)-amide,

2-oxo-3-[5-(3-pyrrolidin-1-yl-propyl)-1*H*-indol-2-ylmethylene]-2,3-dihydro-1*H*-indole-5-carboxylic acid,

2-oxo-3-[5-(3-pyrrolidin-1-yl-propyl)-1*H*-indol-2-ylmethylene]-2,3-dihydro-1*H*-indole-6-carboxylic acid,

({2-oxo-3-[5-(3-pyrrolidin-1-yl-propyl)-1*H*-indol-2-ylmethylene]-2,3-dihydro-1*H*-indole-5-carbonyl}-amino)-acetic acid,

({2-oxo-3-[5-(3-pyrrolidin-1-yl-propyl)-1*H*-indol-2-ylmethylene]-2,3-dihydro-1*H*-indole-6-carbonyl}-amino)-acetic acid,

2-({2-oxo-3-[5-(3-pyrrolidin-1-yl-propyl)-1*H*-indol-2-ylmethylene]-2,3-dihydro-1*H*-indole-5-carbonyl}-amino)-propionic acid,

3-methyl-2-({2-oxo-3-[5-(3-pyrrolidin-1-yl-propyl)-1*H*-indol-2-ylmethylene]-2,3-dihydro-1*H*-indole-5-carbonyl}-amino)-butyric acid,

2-({2-oxo-3-[5-(3-pyrrolidin-1-yl-propyl)-1*H*-indol-2-ylmethylene]-2,3-dihydro-1*H*-indole-6-carbonyl}-amino)-propionic acid,

and 3-methyl-2-({2-oxo-3-[5-(3-pyrrolidin-1-yl-propyl)-1*H*-indol-2-ylmethylene]-2,3-dihydro-1*H*-indole-6-carbonyl}-amino)-butyric acid;  
or a pharmaceutically acceptable salt thereof.

20. A method of modulating the function of a protein kinase or a protein phosphatase in vitro or in vivo with an indolinone compound of any one of claims 1, 7, 8, or 16 comprising the step of contacting cells expressing said protein kinase or a protein phosphatase with said compound.

21. A method for treating an abnormal condition mediated by unregulated protein kinase or a protein phosphatase signal transduction, the method comprising administering to an organism in need thereof a therapeutically effective amount of a compound of any one of claims 1, 7, 8, or 16.

22. The method of claim 21, wherein said organism is a mammal and said abnormal condition is selected from the group consisting of blood vessel proliferative disorders, mesangial cell proliferative disorders, and fibrotic disorders.

23. The method of claim 22, wherein said abnormal condition is cancer.

24. The method of Claim 23 wherein said cancer is selected from the group consisting of squamous cell carcinoma, astrocytoma, Kaposi's sarcoma, glioblastoma, lung cancer, bladder cancer, head and neck cancer, melanoma, ovarian cancer, prostate cancer, breast cancer, small-cell lung cancer, glioma, colorectal cancer, genitourinary cancer and gastrointestinal cancer.

25. The method of Claim 22 wherein said abnormal condition is selected from the group consisting of diabetes, an autoimmune disorder, a hyperproliferation disorder, restenosis, fibrosis, psoriasis, von Heppel-Lindau disease, osteoarthritis, rheumatoid arthritis, angiogenesis, an inflammatory disorder, an immunological disorder and a cardiovascular disorder.